Citation Impact
Citing Papers
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
2013 StandoutNobel
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
2010 StandoutNobel
Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
2009
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3 + CD25 + CD4 + regulatory T cells
2005 StandoutNobel
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
1998 Standout
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Untangling the ErbB signalling network
2001 Standout
HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice
2003
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
1998
Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
2000
Immunotherapy of cancer in 2012
2012
HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer
1997
Therapeutic HER2/Neu DNA Vaccine Inhibits Mouse Tumor Naturally Overexpressing Endogenous Neu
2004
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
2009
Combinatorial Cancer Immunotherapy
2006
Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity
1998
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
2010 Standout
Immunotherapy for Lung Cancer
2008
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
1998 Standout
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias
1995
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Lung Cancer
2008 Standout
Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer
2006
The relationship between the rate of entry into S phase, concentration of DNA polymerase α, and cell volume in human diploid fibroblast-like monokaryon cells
1991
Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma
2004
DNA polymerase α and the regulation of entry into S phase in heterokaryons
1991
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
1997
A Translational View of the Molecular Pathogenesis of Lung Cancer
2007
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb
2007
Malignant Gliomas in Adults
2008 Standout
Infectious and immunosuppressive complications of purine analog therapy.
1995
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
2011 StandoutNobel
White Americans' Genetic Lay Theories of Race Differences and Sexual Orientation: Their Relationship with Prejudice toward Blacks, and Gay Men and Lesbians
2006
Cancer immunotherapy comes of age
2011 StandoutNature
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
2002 Standout
Programmed Cell Death as a Mechanism of CD4 and CD8 T Cell Deletion in AIDS: Molecular Control and Effect of Highly Active Anti‐retroviral Therapy
1999 StandoutNobel
Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes
1998 Standout
Therapeutic Cancer Vaccines
2013
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
1996 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
The Immunobiology of Cancer Immunosurveillance and Immunoediting
2004 Standout
In vivoblockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
1999 StandoutNobel
Climate change, migration and adaptation in Funafuti, Tuvalu
2008 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2002 StandoutScience
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
1999 StandoutNobel
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
2012 StandoutNobel
Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
1995
Characterization of a messenger RNA polynucleotide vaccine vector.
1995
Alphavirus-based expression vectors: strategies and applications.
1996 StandoutNobel
Environmental Concerns and International Migration
1996
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
The Unenlarged Lymph Nodes of HIV-1–infected, Asymptomatic Patients with High CD4 T Cell Counts Are Sites for Virus Replication and CD4 T Cell Proliferation. The Impact of Highly Active Antiretroviral Therapy
1998 StandoutNobel
Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference
2007 StandoutNobel
Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia
1997 StandoutScience
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Cancer Genome Landscapes
2013 StandoutScience
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response
2000 StandoutNobel
Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice
2003
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Functional Significance of Cell Volume Regulatory Mechanisms
1998 Standout
Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
1995
Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites
2016 Standout
Current status of immunotherapy for the treatment of lung cancer.
2010
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients
2005
Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis
2001
Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
2005 StandoutNobel
A sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expressionin vivo
1995
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
1999 StandoutNobel
Human tumor antigens recognized by T lymphocytes.
1996
Works of Joseph Wayne Smith being referenced
In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
1994
Flow cytometric analysis of small DNA content differences in heterogeneous cell populations: Human amniotic fluid cells
1984
Kinetics of Recovery of CD4+ T Cells in Peripheral Blood of Deoxycoformycin-Treated Patients
1991
Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines in Non-Small-Cell Lung Cancer
2004
Induction of T Cells Specific for the Mutated Segment of Oncogenic P21ras Protein by Immunization In Vivo with the Oncogenic Protein
1993
The Lives to Come: The Genetic Revolution and Human Possibilities.
1997
Climatic change and migration from Oceania: Implications for Australia, New Zealand and the United States of America
1995